Literature DB >> 24965473

A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity.

Ari Watt1, Felicien Moukambi2, Logan Banadyga1, Allison Groseth3, Julie Callison1, Astrid Herwig2, Hideki Ebihara1, Heinz Feldmann4, Thomas Hoenen5.   

Abstract

UNLABELLED: Work with infectious Ebola viruses is restricted to biosafety level 4 (BSL4) laboratories, presenting a significant barrier for studying these viruses. Life cycle modeling systems, including minigenome systems and transcription- and replication-competent virus-like particle (trVLP) systems, allow modeling of the virus life cycle under BSL2 conditions; however, all current systems model only certain aspects of the virus life cycle, rely on plasmid-based viral protein expression, and have been used to model only single infectious cycles. We have developed a novel life cycle modeling system allowing continuous passaging of infectious trVLPs containing a tetracistronic minigenome that encodes a reporter and the viral proteins VP40, VP24, and GP1,2. This system is ideally suited for studying morphogenesis, budding, and entry, in addition to genome replication and transcription. Importantly, the specific infectivity of trVLPs in this system was ∼ 500-fold higher than that in previous systems. Using this system for functional studies of VP24, we showed that, contrary to previous reports, VP24 only very modestly inhibits genome replication and transcription when expressed in a regulated fashion, which we confirmed using infectious Ebola viruses. Interestingly, we also discovered a genome length-dependent effect of VP24 on particle infectivity, which was previously undetected due to the short length of monocistronic minigenomes and which is due at least partially to a previously unknown function of VP24 in RNA packaging. Based on our findings, we propose a model for the function of VP24 that reconciles all currently available data regarding the role of VP24 in nucleocapsid assembly as well as genome replication and transcription. IMPORTANCE: Ebola viruses cause severe hemorrhagic fevers in humans, with no countermeasures currently being available, and must be studied in maximum-containment laboratories. Only a few of these laboratories exist worldwide, limiting our ability to study Ebola viruses and develop countermeasures. Here we report the development of a novel reverse genetics-based system that allows the study of Ebola viruses without maximum-containment laboratories. We used this system to investigate the Ebola virus protein VP24, showing that, contrary to previous reports, it only modestly inhibits virus genome replication and transcription but is important for packaging of genomes into virus particles, which constitutes a previously unknown function of VP24 and a potential antiviral target. We further propose a comprehensive model for the function of VP24 in nucleocapsid assembly. Importantly, on the basis of this approach, it should easily be possible to develop similar experimental systems for other viruses that are currently restricted to maximum-containment laboratories.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24965473      PMCID: PMC4178905          DOI: 10.1128/JVI.01272-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Establishment and application of an infectious virus-like particle system for Marburg virus.

Authors:  Jörg Wenigenrath; Larissa Kolesnikova; Thomas Hoenen; Eva Mittler; Stephan Becker
Journal:  J Gen Virol       Date:  2010-01-13       Impact factor: 3.891

2.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

3.  Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling.

Authors:  Mathieu Mateo; St Patrick Reid; Lawrence W Leung; Christopher F Basler; Viktor E Volchkov
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

4.  VP40 octamers are essential for Ebola virus replication.

Authors:  Thomas Hoenen; Viktor Volchkov; Larissa Kolesnikova; Eva Mittler; Joanna Timmins; Michelle Ottmann; Olivier Reynard; Stephan Becker; Winfried Weissenhorn
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.

Authors:  St Patrick Reid; Lawrence W Leung; Amy L Hartman; Osvaldo Martinez; Megan L Shaw; Caroline Carbonnelle; Viktor E Volchkov; Stuart T Nichol; Christopher F Basler
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Generation of biologically contained Ebola viruses.

Authors:  Peter Halfmann; Jin Hyun Kim; Hideki Ebihara; Takeshi Noda; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-22       Impact factor: 11.205

7.  The RING domain and the L79 residue of Z protein are involved in both the rescue of nucleocapsids and the incorporation of glycoproteins into infectious chimeric arenavirus-like particles.

Authors:  Juan Cruz Casabona; Jesica M Levingston Macleod; Maria Eugenia Loureiro; Guillermo A Gomez; Nora Lopez
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

8.  Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome.

Authors:  Shinji Watanabe; Takeshi Noda; Peter Halfmann; Luke Jasenosky; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

9.  In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein.

Authors:  Hideki Ebihara; Steven Theriault; Gabriele Neumann; Judie B Alimonti; Joan B Geisbert; Lisa E Hensley; Allison Groseth; Steven M Jones; Thomas W Geisbert; Yoshihiro Kawaoka; Heinz Feldmann
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

10.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Authors:  Thomas W Geisbert; Amy C H Lee; Marjorie Robbins; Joan B Geisbert; Anna N Honko; Vandana Sood; Joshua C Johnson; Susan de Jong; Iran Tavakoli; Adam Judge; Lisa E Hensley; Ian Maclachlan
Journal:  Lancet       Date:  2010-05-29       Impact factor: 79.321

View more
  53 in total

1.  Double Plant Homeodomain Fingers 2 (DPF2) Promotes the Immune Escape of Influenza Virus by Suppressing Beta Interferon Production.

Authors:  Dongjo Shin; Jihye Lee; Ji Hoon Park; Ji-Young Min
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

2.  Ebola Virus Inclusion Body Formation and RNA Synthesis Are Controlled by a Novel Domain of Nucleoprotein Interacting with VP35.

Authors:  Tsuyoshi Miyake; Charlotte M Farley; Benjamin E Neubauer; Thomas P Beddow; Thomas Hoenen; Daniel A Engel
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

3.  Analysis of the highly diverse gene borders in Ebola virus reveals a distinct mechanism of transcriptional regulation.

Authors:  Kristina Brauburger; Yannik Boehmann; Yoshimi Tsuda; Thomas Hoenen; Judith Olejnik; Michael Schümann; Hideki Ebihara; Elke Mühlberger
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

4.  VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.

Authors:  Toni M Schwarz; Megan R Edwards; Audrey Diederichs; Joshua B Alinger; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

5.  The Integrity of the YxxL Motif of Ebola Virus VP24 Is Important for the Transport of Nucleocapsid-Like Structures and for the Regulation of Viral RNA Synthesis.

Authors:  Yuki Takamatsu; Larissa Kolesnikova; Martin Schauflinger; Takeshi Noda; Stephan Becker
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

6.  Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells.

Authors:  Markus Hoffmann; Inga Nehlmeier; Constantin Brinkmann; Verena Krähling; Laura Behner; Anna-Sophie Moldenhauer; Nadine Krüger; Julia Nehls; Michael Schindler; Thomas Hoenen; Andrea Maisner; Stephan Becker; Stefan Pöhlmann
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

7.  Evolution and Antiviral Specificities of Interferon-Induced Mx Proteins of Bats against Ebola, Influenza, and Other RNA Viruses.

Authors:  Jonas Fuchs; Martin Hölzer; Mirjam Schilling; Corinna Patzina; Andreas Schoen; Thomas Hoenen; Gert Zimmer; Manja Marz; Friedemann Weber; Marcel A Müller; Georg Kochs
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

8.  The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target.

Authors:  Jonathan J Madara; Ziying Han; Gordon Ruthel; Bruce D Freedman; Ronald N Harty
Journal:  Future Virol       Date:  2015-05       Impact factor: 1.831

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

Review 10.  Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis.

Authors:  Logan Banadyga; Michael A Dolan; Hideki Ebihara
Journal:  J Mol Biol       Date:  2016-05-14       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.